Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by G1 Therapeutics
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
August 08, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
July 25, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
June 24, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
May 28, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
May 23, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
May 22, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
May 01, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
May 01, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
February 28, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
February 12, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
December 05, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
November 29, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
November 01, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
October 18, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
October 27, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
October 16, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
August 02, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
July 31, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
June 04, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer
May 16, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)
May 10, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
May 03, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
March 01, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)
February 13, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
January 09, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment
December 07, 2022
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Closing of Offering of Common Stock
November 22, 2022
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Pricing of Offering of Common Stock
November 17, 2022
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Proposed Public Offering of Common Stock
November 17, 2022
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright